Key Takeaways
- Bioxytran has developed a water-soluble galectin antagonist, which is in preclinical trials as a potential treatment for Highly Pathogenic Avian Influenza (HPAI), or Bird Flu.
- The treatment could prevent the spread of H5N1 in egg-laying chickens, reducing the need for mass culling during outbreaks.
- Galectin antagonists block viral entry into cells, a mechanism previously tested in human Phase 2 clinical trials and in vitro studies.
- The company is seeking partnerships with organizations and government agencies to accelerate the development and deployment of the treatment.
- If successful, this approach could help protect the poultry industry, reduce economic losses, and safeguard the global food supply.
A New Approach to Managing Bird Flu Outbreaks
Preventing Mass Culling with Galectin Antagonists
Bioxytran Inc. (OTCQB: BIXT), a clinical-stage biotechnology company, has announced a potential game-changing treatment for Highly Pathogenic Avian Influenza (HPAI), commonly known as Bird Flu.
The company’s water-soluble galectin antagonist is being developed to neutralize the virus in egg-laying chickens, preventing viral entry into cells. If proven effective, the treatment could eliminate the need for mass culling, a widely used but economically damaging method of controlling outbreaks.
“This breakthrough represents a significant step forward in our mission to combat viral diseases. By targeting the virus directly, we can protect both animal health and the global food supply.” — David Platt, CEO, Bioxytran Inc.
The Science Behind the Treatment
How Galectin Antagonists Work
Galectin antagonists function by blocking viral adhesion, preventing the virus from entering host cells. This mechanism has been demonstrated in Phase 2 human clinical trials and in vitro studies.
Key advantages of Bioxytran’s approach include:
- Direct viral neutralization – The treatment targets the virus before it can spread.
- Potential cross-species effectiveness – The mechanism has been observed in mammals, which suggests it may be highly effective in chickens.
- Lower risk of viral mutations – By blocking spike proteins, the treatment may reduce the chance of viral adaptation and resistance.
“Our galectin antagonists block the spike proteins outside the cell. This may stop the spread of the disease right away.” — David Platt, CEO, Bioxytran Inc.
Reducing Economic Losses in the Poultry Industry
Addressing a Multi-Billion-Dollar Problem
Bird Flu outbreaks cost the poultry industry billions annually, with current protocols requiring the culling of entire flocks to prevent further spread. Bioxytran’s novel treatment could provide:
✅ A sustainable alternative to mass culling
✅ Reduced financial losses for poultry farmers
✅ Greater stability in the global food supply
By developing a targeted antiviral solution, Bioxytran aims to offer a more effective and scalable response to HPAI outbreaks.
Next Steps: Seeking Partnerships for Development
Accelerating Deployment Through Collaboration
Bioxytran is currently working to optimize the treatment’s delivery method and is actively seeking partnerships with organizations and government agencies to support:
- Further research and validation
- Regulatory approval processes
- Large-scale manufacturing and distribution
